MedMira to Participate in Military Health System Research Symposium

    




 HALIFAX, Aug. 13, 2012 /CNW/ - MedMira Inc., (MedMira) , a  developer of rapid diagnostic technology and solutions, announced today  that it is participating in the Military Health System Research  Symposium (MHSRS) taking place August 13-16, 2012 in Fort Lauderdale,  FL. During the symposium, MedMira will discuss and demonstrate its  unique multiplex rapid diagnostics which are critical tools in the  treatment and care of individuals wounded in combat. 

 MHSRS is the premier scientific meeting to address the unique medical  needs of the warfighter. The symposium is a collaborative environment  for military medical care providers with deployment experience,  Department of Defense (DoD) scientists, academia, and industry to  facilitate discussions and address the advancement of research and  health care development in areas of Combat Casualty Care, Military  Operational Medicine, Clinical and Rehabilitative Medicine, and  Military Infectious Disease Research Programs. 

 "This event provides us with an ideal opportunity to showcase our rapid  diagnostics and technology platform and allows us to continue building  key relationships with military healthcare personnel within the US Army  and other military organizations around the world," said Hermes Chan,  CEO, MedMira Inc.  "MHSRS attendees will be keen to see and learn more  about our Multiplo Rapid HBV/HIV/HCV Antibody Test, for which we were  recently awarded a US Army contract to advance, fully commercialize,  and obtain US Food and Drug Administration approval." 

 In July 2012, MedMira was awarded a U.S. Army Medical Research  Acquisition Activity (USAMRAA) contract valued at USD$4,266,144 to  advance and fully commercialize its multiple rapid test that  simultaneously detects three of the most serious infectious diseases,  namely HIV-1/2, Hepatitis B, and C antibodies within three minutes  using just a small drop of blood. 

 About MedMira 

 MedMira is a leading developer and manufacturer of flow-through rapid  diagnostics and technologies. The Company's tests provide hospitals,  labs, clinics and individuals with reliable, rapid diagnosis for  diseases such as HIV and hepatitis C in just three minutes. The  company's tests are sold under the Reveal®, Multiplo™ and Miriad brands  in global markets. MedMira's rapid flow-through HIV test is the only  one in the world to achieve regulatory approvals in Canada, the United  States, China and the European Union. MedMira's corporate offices and  manufacturing facilities are located in Halifax, Nova Scotia, Canada.  For more information visit MedMira's website at www.medmira.com. 

 This news release contains forward-looking statements, including  statements relating to growth in the Company's business, earnings and  profitability, and trends in demand for the Company's products, which  involve risk and uncertainties and reflect the Company's current  expectation regarding future events including statements regarding  possible future growth and new business opportunities.  Actual events  could materially differ from those projected herein and depend on a  number of factors including, but not limited to, changing market  conditions, successful and timely completion of clinical studies,  uncertainties related to the regulatory approval process, establishment  of corporate alliances and other risks detailed from time to time in  the company quarterly filings. 

 Neither TSX Venture Exchange nor its Regulation Services Provider (as  that term is defined in the policies of the TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release.  

MEDMIRA INC.


CONTACT:  MedMira Contact:Andrea Young, Corporate CommunicationsTel: 902-450-1588Email: [e-mail] 


    

Copyright